Claims for Patent: 7,855,204
✉ Email this page to a colleague
Summary for Patent: 7,855,204
Title: | Derivatives of gefitinib |
Abstract: | This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases. |
Inventor(s): | Tung; Roger (Lexington, MA) |
Assignee: | Concert Pharmaceuticals Inc. (Lexington, MA) |
Application Number: | 12/358,238 |
Patent Claims: | 1. A compound of the formula A ##STR00014## or a pharmaceutically acceptable salt thereof, wherein the compound is selected from any one of the compounds depicted in the following
Table: TABLE-US-00004 TABLE Cmpd Y.sup.1 = Y.sup.2 Y.sup.3 = Y.sup.4 Y.sup.5 = Y.sup.6 Y.sup.7 = Y.sup.8 R.sup.1 R.sup.2 R.sup.3 101 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 F 102 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 F 104 H H H H CD.sub.3
CH.sub.2CH.sub.2CH.sub.2 F 108 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 H 109 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 H 110 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 H 111 H H H H CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 H 112 D D D D CD.sub.3
CD.sub.2CD.sub.2CD.sub.2 H 113 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 H 114 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 H 115 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OH 116 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OH 117 D D D D CD.sub.3
CH.sub.2CH.sub.2CH.sub.2 OH 118 H H H H CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 OH 119 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OH 120 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OH 121 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 OH 122 D D D D CD.sub.3
CD.sub.2CD.sub.2CD.sub.2 OCD.sub.3 123 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OCD.sub.3 124 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 OCD.sub.3 125 H H H H CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 OCD.sub.3 126 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2
OCD.sub.3 127 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OCD.sub.3 128 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 OCD.sub.3 129 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OCH.sub.3 130 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OCH.sub.3 131 D D D D CD.sub.3
CH.sub.2CH.sub.2CH.sub.2 OCH.sub.3 132 H H H H CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 OCH.sub.3 133 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OCH.sub.3 134 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 OCH.sub.3 135 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2
OCD.sub.3 136 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Cl 137 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Cl 138 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 Cl 139 H H H H CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 Cl 140 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Cl
141 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Cl 142 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 Cl 143 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Br 144 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Br 145 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 Br 146 H H H
H CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 Br 147 D D D D CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Br 148 H H H H CD.sub.3 CD.sub.2CD.sub.2CD.sub.2 Br 149 D D D D CD.sub.3 CH.sub.2CH.sub.2CH.sub.2 Br.
2. The compound of claim 1, wherein any atom not designated as deuterium is present at its natural isotopic abundance. 3. A pyrogen-free pharmaceutical composition comprising as a first therapeutic agent a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 4. The composition of claim 3, further comprising a second therapeutic agent useful in the treatment of a patient suffering from non-small cell lung cancer. 5. The composition of claim 4, wherein the second therapeutic agent is selected from anastrozole, cediranib, bexarotene, calcitriol, capecitabine, carboplatin, cefixime, celecoxib, canertinib, cisplatin, dexamethasone, docetaxel, cetuximab, etoposide, everolimus, fluorouracil, fulvestrant, gemcitabine, irinotecan, leucovorin, loperamide, oxaliplatin, paclitaxel, PEG-interferon alpha, pemetrexed, raltitrexed, simvastatin, sirolimus, sunitinib, tamoxifen, temozolomide, topotecan, trastuzumab, and vinorelbine. 6. A method of treating a patient suffering from, or susceptible to, non-small cell lung cancer comprising the step of administering to the patient in need thereof a composition of claim 3. 7. The method of claim 6, wherein the patient is a smoker. 8. The method of claim 6, wherein the patient is a non-smoker. 9. The method of claim 6, further comprising the additional step of co-administering to the patient in need thereof a second therapeutic agent useful in the treatment of non-small cell lung cancer. 10. The method of claim 9, wherein the second therapeutic agent is selected from AZD2171, bexarotene, carboplatin, celecoxib, cisplatin, docetaxel, cetuximab, everolimus, fulvestrant, gemcitabine, paclitaxel, pemetrexed, simvastatin, sirolimus, and vinorelbine. |
Details for Patent 7,855,204
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2028-01-22 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2028-01-22 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2028-01-22 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2028-01-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.